



Imagine a world where stroke, specifically hemorrhagic stroke, **was no longer so devastating**

Following an intracerebral hemorrhage (ICH), brain bleeding initiates inflammation and blood clots, which frequently exacerbate the injury, resulting in poor outcomes.

BIOXODES is investigating a new treatment option named **BIOX-101** (Ir-CPI), which focuses on addressing this inflammation and undesirable blood clots, potentially enhancing the **recovery of patients**.



BIOX-101

- A strong anticlotting effect with no increased bleeding risk!
- Anti-inflammatory effect (neutrophil inhibition).
- Specifically designed for ICH: fits the need during the first 72h after disease onset.



Key preclinical findings (ICH mouse model)

- BIOX-101 does not worsen lesion or bleeding after ICH as compared to placebo.
- BIOX-101 reduces harmful inflammation & protects neuronal cells from damage.
- BIOX-101 improves functional recovery as compared to placebo.



Potential impact

- Each year, > 3 million people worldwide experience ICH, resulting in **2.8 million deaths**.
- There is no specific treatment available !

BIOX-101 could be a **game-changer** in hemorrhagic stroke treatment. BIOXODES is currently running a **Phase 2a trial in Belgium** with ICH patients to test BIOX-101, offering a **breakthrough hope** for millions of patients around the world.



Want to invest?
+32 496 59 03 54



Our Location
Gosselies Biopark, Belgium



Visit Our Website
www.bioxodes.com

